Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ivanshu Jain

Addiction Psychiatry Terrell, TX Medical Doctor

NPI 1558776138 CMS profile 2790317

Terrell State Hospital, 1200 E Brin St, Terrell, TX 75160

Open in the dashboard

General payments

$1,762

9 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ivanshu Jain of Terrell, TX is reported in the CMS Open Payments database as having received $1,762 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Addiction Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,728 7
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivanshu Jain
  • Addiction Psychiatry median
  • Middle half of Addiction Psychiatry
  • National median

In program year 2025, general payments to Ivanshu Jain were reported at $0. Among 180 Addiction Psychiatry profiles paid that year, the median was $138 and the middle half received between $45 and $421.

Show as a table
Year Ivanshu Jain Addiction Psychiatry median Middle half National median
2019 $34 $142 $56–$476 $163
2020 $0 $78 $21–$210 $114
2021 $0 $112 $35–$458 $132
2022 $0 $113 $39–$343 $149
2023 $0 $134 $47–$429 $160
2024 $1,728 $129 $42–$349 $164
2025 $0 $138 $45–$421 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Neuronetics, Inc. $1,632 6 payments
  2. Tempus AI, Inc $96 1 payment
  3. Sunovion Pharmaceuticals Inc. $20 1 payment
  4. Alkermes, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $1,056 1 payment
  2. Food and Beverage $706 8 payments
Products named General payments · program years 2019–2024
  1. Neurostar TMS Therapy System $1,632 6 payments
  2. LATUDA $20 1 payment
  3. ARISTADA Cns $14 1 payment
  4. ARISTADA Cns $14 1 payment
  5. ARISTADA Cns $14 1 payment
  6. ARISTADA Cns $14 1 payment
  7. ARISTADA INITIO $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

109

Median for Psychiatry: 574

Drug cost

$998

Median for Psychiatry: $27,624

Branded share of claims

10.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Haloperidol Generic 13 $354
Lorazepam Generic 30 $175
Quetiapine Fumarate Generic 15 $157
Divalproex Sodium Er Divalproex Sodium Brand 11 $110
Risperidone Generic 17 $81
Diphenhydramine Hcl Generic 12 $61
Trazodone Hcl Generic 11 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,442

Medicare's payments for the services billed

Medicare patients

11

Average age 37

Services billed

38

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Ischemic heart disease 0%
Atrial fibrillation 0%
Chronic kidney disease 0%
COPD 0%
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record